Expression of pSTAT3 and PD-L1 in extranodal NK/T cell lymphoma and its clinical significance
10.3760/cma.j.cn112151-20200205-00066
- VernacularTitle:pSTAT3和PD-L1在结外NK/T细胞淋巴瘤中的表达及意义
- Author:
Fen ZHANG
1
;
Donglan LUO
;
Yu CHEN
;
Jinhai YAN
;
Luqiao LUO
;
Jian LIU
;
Yanhui LIU
Author Information
1. 广东省人民医院（广东省医学科学院）病理医学部病理科, 广州 510080
- Keywords:
Lymphoma, extranodal NK-T-cell;
Prognosis;
Molecular targeted therapy
- From:
Chinese Journal of Pathology
2020;49(10):999-1002
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the expression of phosphates signal transducer and activator of transcription 3 (pSTAT3) and programmed death ligand-1 (PD-L1) in extranodal NK/T cell lymphomas (ENKTCL) and the relationships of pSTAT3 and PD-L1 expression with the clinicopathological characteristics and prognosis of ENKTCL.Methods:Fifty-one cases of ENKTCL diagnosed at Guangdong Provincial People′s Hospital from June 2015 to February 2019 were included in the study. The expression of pSTAT3 and PD-L1 was examined using immunohistochemistry.Results:There were 35 males and 16 females, ranging from 18 to 85 years old with a median age of 47 years. The positive rates of pSTAT3 and PD-L1 expression were 68.6% (35/51) and 76.5% (39/51), respectively. pSTAT3 expression was correlated with PD-L1 expression ( P=0.033, R=0.322), while there were no associations of pSTAT3 and PD-L1 expression with the clinicopathological characteristics of ENKTCL, including age, sex, clinical site, B symptom, Ann Arbor stage, LDH value, EBV DNA load of peripheral blood and international proliferation index score. Kaplan-Meier survival analysis showed the prognoses of the pSTAT3 and PD-L1 positive groups were slightly better than the respective negative groups, but the differences were not significantly ( P>0.05). Conclusions:pSTAT3 is highly expressed in extranodal NK/T cell lymphoma and related to the expression of PD-L1, which provides a potential target and rationale for combinations of targeted therapies and immune checkpoint blockade inhibitors in the treatment of ENKTCL.
